Application of continuous renal replacement therapy during the perioperative period of lung transplantation
10.12464/j.issn.1674-7445.2026109
- VernacularTitle:连续性肾脏替代治疗在肺移植围手术期的应用
- Author:
Mochi WANG
1
;
Zihan CHEN
1
;
Xinru HE
1
;
Ranming MA
1
;
Chunxiao HU
1
Author Information
1. Wuxi Medical Center of Nanjing Medical University, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Department of Anesthesiology of Wuxi People's Hospital, Wuxi 214023, China.
- Publication Type:ReviewArticle
- Keywords:
Lung transplantation;
Continuous renal replacement therapy;
Acute kidney injury;
Primary graft dysfunction;
Ischemia-reperfusion injury;
Fluid management;
Extracorporeal membrane oxygenation;
End-stage lung disease
- From:
Organ Transplantation
2026;17(6):1025-1032
- CountryChina
- Language:Chinese
-
Abstract:
The treatment options for patients with end-stage lung disease are limited. Lung transplantation is currently the only radical treatment that can significantly improve long-term survival. Acute kidney injury during the perioperative period is one of the most common serious complications after lung transplantation, and its occurrence is closely related to the progression of chronic kidney disease and the increase in fatality after surgery. It has become an important risk factor affecting the prognosis of patients. Continuous renal replacement therapy (CRRT) can achieve multi-organ support through continuous and stable solute clearance and volume regulation. However, there are still many controversies regarding the indications, initiation timing and management strategies of CRRT in the perioperative period of lung transplantation. This article reviews the core principles of CRRT, the key points of clinical application, anticoagulation management and research progress in the perioperative period of lung transplantation, with the aim of providing evidence-based basis for the clinical formulation of individualized perioperative CRRT plans and improving the prognosis of lung transplant recipients.
